IL17A, interleukin 17A, 3605

N. diseases: 1074; N. variants: 19
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0949690
Disease: Spondylarthritis
Spondylarthritis
0.300 Biomarker disease BEFREE Despite a ballooning therapeutic tool box, treatment responses to newer biologic agents and oral small molecules in psoriatic arthritis (PsA) and spondyloarthritis (SpA) are of similar magnitude to those observed with anti-Tumor Necrosis Factor (TNF) medications (1, 2).The PsA and SpA therapeutic outcomes stand in marked contrast to those reported in psoriasis where blockade of molecules in the IL-23/IL-17 pathway often provide prolonged, deep responses and in some cases even remission (3). 31736273 2020
CUI: C0949690
Disease: Spondylarthritis
Spondylarthritis
0.300 Biomarker disease BEFREE IL-17 Inhibition in Spondyloarthritis Associates with Subclinical Gut Microbiome Perturbations and a Distinctive IL-25-Driven Intestinal Inflammation. 31729183 2020
CUI: C0949690
Disease: Spondylarthritis
Spondylarthritis
0.300 Biomarker disease BEFREE IL-17A blockade was performed in HLA-B27/human β<sub>2</sub> -microglobulin (hβ<sub>2</sub> m)-transgenic rats, which served as a model for SpA in both prophylactic and therapeutic settings. 30390386 2019
CUI: C0949690
Disease: Spondylarthritis
Spondylarthritis
0.300 Biomarker disease BEFREE The recent introduction of antibodies blocking IL-17 has expanded the therapeutic options for SpA, as well as psoriasis and psoriatic arthritis. 30941119 2019
CUI: C0949690
Disease: Spondylarthritis
Spondylarthritis
0.300 Biomarker disease BEFREE RORγt inhibition selectively targets IL-17 producing iNKT and γδ-T cells enriched in Spondyloarthritis patients. 30602780 2019
CUI: C0949690
Disease: Spondylarthritis
Spondylarthritis
0.300 Biomarker disease BEFREE Murine models of interleukin (IL)-23-driven spondyloarthritis (SpA) have demonstrated entheseal accumulation of γδT-cells which were responsible for the majority of local IL-17A production. 31530557 2019
CUI: C0949690
Disease: Spondylarthritis
Spondylarthritis
0.300 Biomarker disease BEFREE TNFi and IL-17Ai may be used in axSpA, but physicians have more experience with TNFi. 31095430 2019
CUI: C0949690
Disease: Spondylarthritis
Spondylarthritis
0.300 Biomarker disease BEFREE Nevertheless, a number of knowledge gaps exist regarding the role of IL-17A in the pathophysiology of spondyloarthritis in man, including its cellular origin, its precise role in discrete disease processes such enthesitis, bone erosion, and bone formation, and the reasons for the discrepant responses to IL-17A inhibition observed in certain other spondyloarthritis manifestations. 31278139 2019
CUI: C0949690
Disease: Spondylarthritis
Spondylarthritis
0.300 Biomarker disease BEFREE Translational data in humans have demonstrated an increase in the number of ILC3s responsive to IL-23 and producing either IL-22 or IL-17 in the gut of SpA patients. 31197599 2019
CUI: C0949690
Disease: Spondylarthritis
Spondylarthritis
0.300 Biomarker disease BEFREE Spondyloarthritis (SpA), a chronic inflammatory, rheumatic disease, and hidradenitis suppurativa (HS), a chronic, debilitating, inflammatory skin disease, share several clinical and pathophysiological features, such as the association with inflammatory bowel disease and elevated cytokine levels IL-17 and TNF-α. 29751976 2019
CUI: C0949690
Disease: Spondylarthritis
Spondylarthritis
0.300 Biomarker disease BEFREE IL-7 is a cytokine whose ability to stimulate IL-17 production in both innate and adaptive immunity cells has made it a promising target not only for a better understanding of the disease as well as an important potential therapeutic target in patients with SpA. 31276000 2019
CUI: C0949690
Disease: Spondylarthritis
Spondylarthritis
0.300 Biomarker disease BEFREE Cytokines from the IL-17 family have been shown to be involved in the pathogenesis of several diseases such as spondyloarthritis, psoriatic arthritis, or psoriasis. 31485194 2019
CUI: C0949690
Disease: Spondylarthritis
Spondylarthritis
0.300 Biomarker disease BEFREE This study was undertaken to characterize the presence and composition of ILCs, and investigate whether these cells are an important source of IL-17A, in the synovial tissue (ST) of patients with SpA. 30260078 2019
CUI: C0949690
Disease: Spondylarthritis
Spondylarthritis
0.300 Biomarker disease BEFREE Clinical improvement in joint counts was associated with a histologic decrease in synovial sublining macrophages (P = 0.028) and neutrophils (P = 0.004), both of which are sensitive synovial biomarkers of inflammatory response in peripheral SpA, as well as with decreased synovial expression of IL-17A messenger RNA (mRNA) (P = 0.010) but not of tumor necrosis factor mRNA. 29869838 2018
CUI: C0949690
Disease: Spondylarthritis
Spondylarthritis
0.300 Biomarker disease BEFREE We aimed to assess the extent to which IL-17A-driven pathology is IL-23 dependent in experimental SpA. 30038617 2018
CUI: C0949690
Disease: Spondylarthritis
Spondylarthritis
0.300 Biomarker disease BEFREE However, the contribution of IL-17-producing γδ T cells to SpA pathogenesis is certainly not an open-and-shut case. 29922283 2018
CUI: C0949690
Disease: Spondylarthritis
Spondylarthritis
0.300 Biomarker disease BEFREE Effects of the IL-23-IL-17 pathway on bone in spondyloarthritis. 30266977 2018
CUI: C0949690
Disease: Spondylarthritis
Spondylarthritis
0.300 Biomarker disease BEFREE Other targeted cytokines associated with IL-17 axis in SpA will also be included. 29670461 2018
CUI: C0949690
Disease: Spondylarthritis
Spondylarthritis
0.300 Biomarker disease BEFREE Interleukin-17A has been identified as a master cytokine in the inflammatory response and pathogenesis of PsA and spondyloarthritis in general. 29187009 2018
CUI: C0949690
Disease: Spondylarthritis
Spondylarthritis
0.300 Biomarker disease BEFREE In this Review, we discuss how IL-17A and IL-17F and their cellular sources might contribute to the immunopathology of SpA. 30006601 2018
CUI: C0949690
Disease: Spondylarthritis
Spondylarthritis
0.300 Biomarker disease BEFREE In this review, we will examine key preclinical studies that demonstrated the mechanistic role of IL-17A in the development SpA and discuss how these observations were translated into clinical practice. 28270233 2017
CUI: C0949690
Disease: Spondylarthritis
Spondylarthritis
0.300 Biomarker disease BEFREE Spondyloarthritis encompasses a group of common inflammatory diseases thought to be driven by IL-17A-secreting type-17 lymphocytes. 29142230 2017
CUI: C0949690
Disease: Spondylarthritis
Spondylarthritis
0.300 Biomarker disease BEFREE Finally, IL-17 and IL-23 inhibitors reduce the clinical manifestations of SpA. 28850053 2017
CUI: C0949690
Disease: Spondylarthritis
Spondylarthritis
0.300 Biomarker disease BEFREE Targeted Delivery of the HLA-B<sup>∗</sup>27-Binding Peptide into the Endoplasmic Reticulum Suppresses the IL-23/IL-17 Axis of Immune Cells in Spondylarthritis. 29463951 2017
CUI: C0949690
Disease: Spondylarthritis
Spondylarthritis
0.300 Biomarker disease BEFREE Knowledge regarding the mechanisms of the IL17-IL23 pathway and its role in spondyloarthritis (SpA) has been pivotal to the development of IL-17 blockade in patients with axial SpA. 28149838 2017